183209-56-5

Upstream product

• 916458-79-2 2-(4-benzyloxyphenyl)ethyl-(2,3,4,6-tetra-O-acetyl)-β-D-glucopyranoside 
• 83-87-4 D-glucose pentaacetate 
• 3947-62-4 2,3,4,5-tetra-O-acetyl-D-glucopyranose 
• 100-39-0 benzyl bromide 
• 501-94-0 p-hydroxyphenethyl alcohol 
• 58609-13-5 4-(benzyloxy)phenylacetic acid benzyl ester 
• 156-38-7 4-hydroxyphenylacetate 
• 74808-10-9 O-(2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl)trichloroacetimidate 
• 61439-59-6 2-(4-benzyloxyphenyl)ethanol 

Downstream Products

• 110344-59-7 2-(4-hydroxyphenyl)ethyl 4-Ο-(E)-Feruloyl-β-D-glucopyranoside 
• 955944-28-2 2-(4-benzyloxyphenyl)ethyl 2,3-di-O-benzyl-β-D-glucopyranoside 
• 955944-29-3 2-(4-benzyloxyphenyl)ethyl 2,3-di-O-benzyl-6-O-[(E)-4-O-benzylferuloyl]-β-D-glucopyranoside 
• 955944-30-6 2-(4-benzyloxyphenyl)ethyl 2,3-di-O-benzyl-4-O-[(E)-4-O-benzylferuloyl]-β-D-glucopyranoside 
• 110978-95-5 2-(4-hydroxyphenyl)ethyl 6-O-(E)-(3-methoxy-4-hydroxy)cinnamoyl β-D-glucopyranoside 
• 916458-86-1 (4-benzyloxyphenyl)ethyl (2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl)-(1->3)-2-O-acetyl-β-D-glucopyranoside 
• 916458-87-2 (4-benzyloxyphenyl)ethyl (2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl)-(1->3)-2-O-acetyl-6-O-tert-butyldimethylsilyl-β-D-glucopyranoside 
• 916458-88-3 (4-benzyloxyphenyl)ethyl (2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl)-(1->3)-2-O-acetyl-4-O-[(E)-3,4-di-O-benzyl]caffeoyl-6-O-tert-butyldimethylsilyl-β-D-glucopyranoside 
• 10338-51-9 Salidroside 

Relevant academic research and scientific papers

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

Method for synthesizing salidroside by using [Rmim][OSO2OR]-Lewis acid ionic liquid system

The invention belongs to the technical field of catalytic synthesis and particularly relates to a method for synthesizing salidroside by using a [Rmim][OSO2OR]-Lewis acid ionic liquid system. According to the method, the salidroside compound is synthesized by using ionic liquid [Rmim][OSO2OR]. The synthesis of the ionic liquid provided by the invention needs only a one-step reaction, and atoms ofraw materials in a synthetic reaction of the ionic liquid are utilized by 100%, and thus, the reaction is an atomic-economical-efficiency reaction with simple and convenient operation. The method provided by the invention is environmentally friendly and is mild in reaction conditions and simple in aftertreatment, the problems such as environmental pollution caused by tedious synthesis of the ionicliquid used during the existing O-Glycosylation of a glycosyl trichloroacetimidate donor by using an ionic liquid system, thermal energy consumption, atom waste and a non-atomic-economical-efficiencyreaction are solved, and meanwhile, the problems such as environmental pollution and tedious aftertreatment caused by the existing salidroside drug chemical-synthesis in organic solvents are solved.

Synthesis, biological activity of salidroside and its analogues

Salidroside is a phenylpropanoid glycoside isolated from Rhodiola rosea L., a traditional Chinese medicinal plant, and has displayed a broad spectrum of pharmacological properties. In this paper, about 18 novel salidroside analogues were prepared through Koenigs-Knorr method, the effects of these compounds over PC12 was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The novel compounds differ in the substituents attached to the benzene ring or in the glycosyl donor. According to the data, compounds (3,5-dimethoxyphenyl)methyl β-D-glucopyranoside and (3,5-dimethoxyphenyl) methyl β-D-galactopyranoside with methoxy group at 3 and 5-positions of the benzene ring were the most viability at concentration of 300 μmol/l and 60 μmol/l, respectively.

Total synthesis of phenylpropanoid glycosides, grayanoside A and syringalide B, through a common intermediate

Phenylpropanoid glycosides are known as bioactive natural products. Two of them, grayanoside A (1) and syringalide B (2), were synthesized through a common intermediate, using benzyl as temporary protecting group following a shorter route.

Synthesis of a benzyl-protected analog of arenarioside, a trisaccharide phenylpropanoid glycoside

A benzyl-protected analog of the phenylpropanoid glycoside arenarioside, (4-benzyloxyphenyl)ethyl α-l-rhamnopyranosyl-(1→3)-4-O-[(E)-3,4-di-O-benzyl-caffeoyl]-[β-d-xylopyranosyl-(1→6)]-β-d-glucopyranoside (22), was synthesized through two different routes from d-glucose. This is the first approach on the synthesis of a trisaccharide phenylpropanoid glycoside, although the benzyl-protecting group in the backbone of the arenarioside analog could not be removed by conventional debenzylation procedures.